Galenica Ltd.

GALE

Equity

ISIN CH0360674466 / Valor 36067446

SIX Swiss Exchange (2026-10-02)

CHF 81.50-0.12%

Galenica Ltd.
UMushroom community rating:

4.00 1 votes No rating yet

NegativeNeutralPositive

About company

Galenica Ltd. is a prominent player in the Swiss healthcare market, operating a comprehensive network of over 20 business units. The company focuses on delivering seamless, efficient, and personalized healthcare solutions to meet the needs of patients and customers. In the 2024 financial year, Galenica reported a 4.7% increase in sales, achieving consolidated net sales of CHF 3,921.1 million. This growth allowed the company to outperform the market and expand its market share across its primary business areas. Galenica's strategic partnerships and robust network position it as a key contributor to the Swiss healthcare sector.

Summarized from source with an LLMView SourceSector: Healthcare

H1 2026 sales

Group net sales increased 7.1% in the first half of 2026, reaching CHF 2,136.5 million.

2025 comparison

For the full year 2025, Galenica Group sales grew 5.5%, indicating accelerating momentum into 2026.

Key growth drivers

The main drivers of H1 2026 growth were strong performance in the pharmacy business and a continued rise in wholesale sales.

Home care performance

Within home care, the “Services & Production” sector grew 9.4% to CHF 63.4 million; the “Diagnostics” sector is reported at CHF 62.2 million and is noted as contributing 3.1% to the sales increase.

Other disclosures / missing items

The provided excerpt lists headings for key figures (including “EBIT adjusted” and number of employees as of 30 June 2026) and references published reports, but does not include adjusted EBIT figures or an employee count in the text supplied.

Summarized from source with an LLMView Source

Key figures

-4.68%1Y

21.1%3Y

24.6%5Y

Performance

16.5%1Y

16.0%3Y

17.5%5Y

Volatility